DK3128997T3 - Bindingmolekyler specifikke for il-21 og anvendelser deraf - Google Patents

Bindingmolekyler specifikke for il-21 og anvendelser deraf Download PDF

Info

Publication number: DK3128997T3
Authority: DK; Denmark
Prior art keywords: binding molecules; molecules specific; specific; binding; molecules
Prior art date: 2014-04-08

Application number

DK15776002.6T

Other languages

English (en)

Inventor

Catherine Ettinger

Jodi Karnell

Melissa Damschroder

Partha Chowdhury

Xiaodong Xiao

Ping Tsui

Reena Varkey

Stacey Drabic

Laura Carter

Ronald Herbst

Qun Du

Brian Michael Naiman

Original Assignee

Boston Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-08

Filing date

2015-04-07

Publication date

2020-08-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54288526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3128997(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-07 Application filed by Boston Pharmaceuticals Inc filed Critical Boston Pharmaceuticals Inc

2020-08-24 Application granted granted Critical

2020-08-24 Publication of DK3128997T3 publication Critical patent/DK3128997T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Dental Preparations (AREA)
Materials For Medical Uses (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK15776002.6T 2014-04-08 2015-04-07 Bindingmolekyler specifikke for il-21 og anvendelser deraf DK3128997T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461976684P	2014-04-08	2014-04-08
PCT/US2015/024650 WO2015157238A2 (en)	2014-04-08	2015-04-07	Binding molecules specific for il-21 and uses thereof

Publications (1)

Publication Number	Publication Date
DK3128997T3 true DK3128997T3 (da)	2020-08-24

Family

ID=54288526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15776002.6T DK3128997T3 (da)	2014-04-08	2015-04-07	Bindingmolekyler specifikke for il-21 og anvendelser deraf

Country Status (24)

Country	Link
US (4)	US10022443B2 (da)
EP (2)	EP3128997B1 (da)
KR (1)	KR102546611B1 (da)
CN (2)	CN111560071B (da)
AU (2)	AU2015244025B2 (da)
CA (2)	CA2948275C (da)
CY (1)	CY1123275T1 (da)
DK (1)	DK3128997T3 (da)
ES (1)	ES2814150T3 (da)
HR (1)	HRP20201377T1 (da)
HU (1)	HUE051676T2 (da)
IL (2)	IL248709B (da)
LT (1)	LT3128997T (da)
MA (2)	MA39821B1 (da)
PL (1)	PL3128997T3 (da)
PT (1)	PT3128997T (da)
RS (1)	RS60795B1 (da)
RU (1)	RU2708336C2 (da)
SG (2)	SG10201913627TA (da)
SI (1)	SI3128997T1 (da)
SM (1)	SMT202000464T1 (da)
TW (1)	TWI665214B (da)
WO (1)	WO2015157238A2 (da)
ZA (1)	ZA201707489B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017223283A1 (en)	2016-06-22	2017-12-28	Icahn School Of Medicine At Mount Sinai	Hcv core and minicore binding molecules
JP6827113B2 (ja)	2017-01-21	2021-02-10	広州白雲山漢方現代薬業有限公司ＧｕａｎｇｚｈｏｕＨａｎｆａｎｇＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
HUE058233T2 (hu)	2017-08-03	2022-07-28	Amgen Inc	Interleukin-21-muteinek és kezelési eljárások
WO2019052562A1 (zh) *	2017-09-15	2019-03-21	科济生物医药（上海）有限公司	Il-4r的融合蛋白及其应用
CN111727197A (zh)	2018-01-12	2020-09-29	美国安进公司	抗pd-1抗体和治疗方法
AU2020291012A1 (en)	2019-06-12	2021-12-16	AskGene Pharma, Inc.	Novel IL-15 prodrugs and methods of use thereof
EP4017594A1 (en)	2019-08-21	2022-06-29	Askgene Pharma, Inc.	Novel il-21 prodrugs and methods of use thereof
BR112022004302A2 (pt) *	2019-09-25	2022-06-21	Surface Oncology Inc	Anticorpos anti-il-27 e usos dos mesmos
CN113321729B (zh) *	2021-07-01	2022-08-30	东大生物技术(苏州)有限公司	一组il-12单克隆抗体及其医药用途
CN116554323B (zh) *	2023-04-27	2024-02-27	中南大学湘雅二医院	人源化抗il21抗体的开发和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3590766C2 (da)	1985-03-30	1991-01-10	Marc Genf/Geneve Ch Ballivet
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de)	1986-01-15	1987-07-16	Ant Nachrichtentech	Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en)	1986-03-14	1997-10-28	Celltech Limited	Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
CA2057923A1 (en)	1989-05-16	1990-11-17	William D. Huse	Co-expression of heteromeric receptors
CA2016841C (en)	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
CA2016842A1 (en)	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5766886A (en)	1991-12-13	1998-06-16	Xoma Corporation	Modified antibody variable domains
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6828422B1 (en)	1995-08-18	2004-12-07	Morphosys Ag	Protein/(poly)peptide libraries
PT859841E (pt)	1995-08-18	2002-11-29	Morphosys Ag	Bibliotecas de proteinas/ (poli) peptidos
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
EP1151012A4 (en) *	1998-11-19	2003-01-08	Smithkline Beecham Corp	ANTAGONIST ANTIBODIES OF RHAMM
CA2339889C (en)	1999-07-02	2012-01-31	Morphosys Ag	Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
CA2406993A1 (en)	2000-03-24	2001-09-27	Micromet Ag	Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US7658921B2 (en)	2000-12-12	2010-02-09	Medimmune, Llc	Molecules with extended half-lives, compositions and uses thereof
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
GB0216648D0 (en)	2002-07-18	2002-08-28	Lonza Biologics Plc	Method of expressing recombinant protein in CHO cells
CN1795009B (zh)	2002-11-07	2014-07-09	伊谬诺金公司	抗-cd33抗体及其用途
US20070092485A1 (en)	2002-11-15	2007-04-26	Zymogenetics, Inc.	Cytokine zalpha11 ligand
EP1603949B9 (en) *	2003-03-14	2011-02-02	Wyeth LLC	Antibodies against human il-21 receptor and uses therefor
EP1725585A2 (en)	2004-03-10	2006-11-29	Lonza Ltd	Method for producing antibodies
EP2428216A3 (en) *	2004-05-20	2012-05-23	ZymoGenetics, Inc.	Methods of treating cancer using IL-21 and monoclonal antibody therapy
RU2007102287A (ru)	2004-08-05	2008-09-10	Вайет (Us)	Антагонисты активности рецептора интерлейкина-21
CN101052419A (zh) *	2004-08-05	2007-10-10	惠氏公司	拮抗白介素－21受体活性
KR20070072510A (ko)	2004-08-30	2007-07-04	론자 바이올로직스 피엘씨	항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
ITRM20040586A1 (it)	2004-11-29	2005-02-28	Giuliani Spa	Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
AU2006341398B9 (en)	2005-11-28	2012-02-02	Zymogenetics, Inc.	IL-21 receptor antagonists
US7691980B2 (en)	2007-01-09	2010-04-06	Bio-Rad Laboratories, Inc.	Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US20080267910A1 (en)	2007-03-09	2008-10-30	Wu Paul W	Rat, rabbit, and cynomolgus monkey IL-21 and IL-22 nucleotide and polypeptide sequences
WO2009047360A1 (en) *	2007-10-11	2009-04-16	Novo Nordisk A/S	Il-21 antibodies
CA2707026C (en) *	2007-12-07	2017-04-11	Zymogenetics, Inc.	Anti-human il-21 monoclonal antibodies
EP2242762B1 (en)	2008-01-18	2015-12-16	Bio-Rad Laboratories, Inc.	Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP2011517319A (ja)	2008-03-03	2011-06-02	ダイアックスコーポレーション	メタロプロテアーゼ１２結合タンパク質
JP5470817B2 (ja)	2008-03-10	2014-04-16	日産自動車株式会社	電池用電極およびこれを用いた電池、並びにその製造方法
RU2011103199A (ru)	2008-06-30	2012-08-10	Онкотерапи Сайенс, Инк. (Jp)	Антитела против cdh3, меченные радиоизотопной меткой, и их применение
US8580714B2 (en)	2009-10-14	2013-11-12	Janssen Biotech, Inc.	Methods of affinity maturing antibodies
PE20140633A1 (es) *	2010-11-19	2014-05-30	Eisai Randd Man Co Ltd	Anticuerpos neutralizadores anti-ccl20
JP6136279B2 (ja)	2013-01-15	2017-05-31	株式会社ジェイテクト	転がり軸受装置
TWI503850B (zh)	2013-03-22	2015-10-11	Polytronics Technology Corp	過電流保護元件
TWI510996B (zh)	2013-10-03	2015-12-01	Acer Inc	控制觸控面板的方法以及使用該方法的可攜式電腦
AR099625A1 (es) *	2014-03-21	2016-08-03	Lilly Co Eli	Anticuerpos de il-21
US9816280B1 (en)	2016-11-02	2017-11-14	Matthew Reitnauer	Portable floor

2015
- 2015-04-07 CN CN202010302182.3A patent/CN111560071B/zh active Active
- 2015-04-07 DK DK15776002.6T patent/DK3128997T3/da active
- 2015-04-07 WO PCT/US2015/024650 patent/WO2015157238A2/en active Application Filing
- 2015-04-07 CN CN201580030200.4A patent/CN106794129B/zh active Active
- 2015-04-07 LT LTEP15776002.6T patent/LT3128997T/lt unknown
- 2015-04-07 PT PT157760026T patent/PT3128997T/pt unknown
- 2015-04-07 SG SG10201913627TA patent/SG10201913627TA/en unknown
- 2015-04-07 MA MA39821A patent/MA39821B1/fr unknown
- 2015-04-07 EP EP15776002.6A patent/EP3128997B1/en active Active
- 2015-04-07 HU HUE15776002A patent/HUE051676T2/hu unknown
- 2015-04-07 RU RU2016143378A patent/RU2708336C2/ru active
- 2015-04-07 CA CA2948275A patent/CA2948275C/en active Active
- 2015-04-07 ES ES15776002T patent/ES2814150T3/es active Active
- 2015-04-07 EP EP20160066.5A patent/EP3689325A1/en active Pending
- 2015-04-07 SI SI201531333T patent/SI3128997T1/sl unknown
- 2015-04-07 US US15/305,093 patent/US10022443B2/en active Active
- 2015-04-07 SM SM20200464T patent/SMT202000464T1/it unknown
- 2015-04-07 MA MA050678A patent/MA50678A/fr unknown
- 2015-04-07 PL PL15776002T patent/PL3128997T3/pl unknown
- 2015-04-07 RS RS20201046A patent/RS60795B1/sr unknown
- 2015-04-07 CA CA3208721A patent/CA3208721A1/en active Pending
- 2015-04-07 SG SG11201609178SA patent/SG11201609178SA/en unknown
- 2015-04-07 KR KR1020167031140A patent/KR102546611B1/ko active Active
- 2015-04-07 AU AU2015244025A patent/AU2015244025B2/en active Active
- 2015-04-08 TW TW104111328A patent/TWI665214B/zh active
2016
- 2016-11-02 IL IL248709A patent/IL248709B/en active IP Right Grant
2017
- 2017-11-06 ZA ZA2017/07489A patent/ZA201707489B/en unknown
2018
- 2018-06-11 US US16/004,795 patent/US10588969B2/en active Active
2019
- 2019-04-09 AU AU2019202447A patent/AU2019202447B2/en active Active
2020
- 2020-02-05 US US16/782,541 patent/US11529415B2/en active Active
- 2020-03-26 IL IL273641A patent/IL273641B/en active IP Right Grant
- 2020-08-24 CY CY20201100787T patent/CY1123275T1/el unknown
- 2020-08-28 HR HRP20201377TT patent/HRP20201377T1/hr unknown
2022
- 2022-12-19 US US18/084,364 patent/US20230201346A1/en active Pending

Also Published As

Publication number	Publication date
CN106794129B (zh)	2020-05-12
US11529415B2 (en)	2022-12-20
HRP20201377T1 (hr)	2021-02-19
AU2019202447A1 (en)	2019-05-02
AU2015244025A1 (en)	2016-11-17
CN106794129A (zh)	2017-05-31
CA2948275C (en)	2023-10-17
IL248709B (en)	2020-08-31
HUE051676T2 (hu)	2021-03-29
EP3128997A4 (en)	2017-12-13
SI3128997T1 (sl)	2020-11-30
WO2015157238A3 (en)	2015-12-10
TWI665214B (zh)	2019-07-11
US20200164069A1 (en)	2020-05-28
MA39821A (fr)	2017-02-15
IL273641A (en)	2020-05-31
NZ762893A (en)	2023-10-27
CN111560071B (zh)	2023-09-05
EP3128997B1 (en)	2020-08-05
WO2015157238A2 (en)	2015-10-15
KR102546611B1 (ko)	2023-06-22
MA50678A (fr)	2020-08-05
MA39821B1 (fr)	2020-09-30
ES2814150T3 (es)	2021-03-26
NZ725735A (en)	2023-09-29
KR20170018814A (ko)	2017-02-20
CY1123275T1 (el)	2021-12-31
SG11201609178SA (en)	2016-12-29
CA3208721A1 (en)	2015-10-15
IL273641B (en)	2021-04-29
SG10201913627TA (en)	2020-03-30
CN111560071A (zh)	2020-08-21
CA2948275A1 (en)	2015-10-15
EP3689325A1 (en)	2020-08-05
AU2015244025B2 (en)	2019-03-21
EP3128997A2 (en)	2017-02-15
RU2016143378A3 (da)	2019-01-21
RU2708336C2 (ru)	2019-12-05
IL248709A0 (en)	2017-03-30
US20180318416A1 (en)	2018-11-08
PT3128997T (pt)	2020-09-04
PL3128997T3 (pl)	2020-12-28
US20230201346A1 (en)	2023-06-29
US10588969B2 (en)	2020-03-17
RS60795B1 (sr)	2020-10-30
LT3128997T (lt)	2020-10-12
RU2016143378A (ru)	2018-05-08
SMT202000464T1 (it)	2020-09-10
US20170173149A1 (en)	2017-06-22
BR112016029734A2 (pt)	2021-11-16
TW201620934A (zh)	2016-06-16
ZA201707489B (en)	2019-06-26
AU2019202447B2 (en)	2020-09-10
US10022443B2 (en)	2018-07-17

Publication	Publication Date	Title
IL278803A (en)	2021-01-31	PD-1 antibody molecules and their use
DK3218406T4 (da)	2024-12-09	Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
IL259585A (en)	2018-07-31	Antibody molecules for april and their uses
IL256416B (en)	2021-12-01	Multispecific antigen-binding molecules and uses thereof
IL246693B2 (en)	2023-03-01	Antibody molecules to tim-3 and their uses
IL246781B (en)	2020-03-31	Antibody molecules against lag-3 and their use
DK3237418T3 (da)	2019-05-13	Triazolopyrimidinforbindelser og anvendelser deraf
DK3177643T3 (da)	2019-07-15	Bispecifikke T-celle-aktiverende antigenbindende molekyler
IL273641B (en)	2021-04-29	Specific binding molecules for il-21 and uses thereof
DK3105250T3 (da)	2020-09-28	Multispecifikke iga-bindingsmolekyler
DK3124611T3 (da)	2020-01-27	Aptamer til fgf2 og anvendelse deraf
FR3026986B1 (fr)	2018-06-29	Livre auto-eclaire